Mumbai: The synthetic peptides, oligonucleotides, and mRNA market is a rapidly expanding sector within the biomolecule industry, driven by advancements in synthesis technologies and the growing demand for personalised medicine. These custom-designed molecules play crucial roles in therapeutics, diagnostics, and research, offering promising avenues for innovation and investment.
The ETPharma Biomolecule Workshop & Connect Mumbai Chapter 2024 will bring together experts to delve into recent progress, challenges, and prospects in synthetic peptides, oligonucleotides, and mRNA. The event explores their immunogenicity, diverse applications, and pivotal role in therapeutic breakthroughs, providing valuable insights into pioneering research and cutting-edge technologies shaping the future of healthcare. The associate partner for the event is Cytiva; exhibit partners are Daicel, Ami Polymer, MR Sanghavi and Thermofisher.
The workshop will commence with the opening remarks by ETPharma, followed by an address by the chief guest, Dr Harish Chander Deputy Director (QC), National Institute of Biologicals, on ‘Exploring Critical Quality Attributes (CQAs) in Complex Biopharmaceuticals’.
Following the guest address, a keynote session on Cracking the Code of Complex Pharmaceuticals: Exploring Critical Quality Attributes in Peptides and Oligonucleotides (CQA‘s & PQA’s) will be delivered by Dr Manoj Pananchukunnath, Chief Scientific Officer, Biocon Limited.
The keynote session will be followed by a session on Oligonucleotides Therapeutics: A full Oligo workflow for process development and beyond by Asis Singh, Nucleic Acid Therapy, Workflow Specialist, India, Cytiva.
The Oligonucleotides Therapeutics – A full Oligo workflow for process development and beyond session will be followed by a session on Current Challenges and Regulatory Insights in Assessment of Immunogenicity of Peptide Products by Dr Ravi Shankara, Senior General Manager R&D, Sun Pharma.
The Current Challenges and Regulatory Insights in Assessment of Immunogenicity of Peptide Products session will be followed by a session on Ensuring Purity and Safety: Innovations in Biomolecule Impurity Characterisation, by Prof Dr Hosahudya N Gopi, Professor of Chemistry, IISER, Pune.
Dr Ravi Shah, Assistant Professor, National Institute of Pharmaceutical Education and Research will conduct a session on Quality Assessment Of Oligonucleotides: Challenges & Opportunities.
The session on Quality Assessment Of Oligonucleotides: Challenges & Opportunities will be followed by a session on Case Study: mRNA vaccine from concept to clinic by Dr Ajay Singh, Head-mRNA, Gennova, Biopharmaceuticals.
Dr Singh’s session will be followed by a session on Zooming inside HOS of in-formulation state Biopharmaceuticals by NMR spectroscopy by Profesor, Ashutosh Kumar, Structural Biology, Department of Bioscience and Bioengineering, Indian Institute of Technology, Bombay, followed by a panel discussion on Harmonising Progress: Catalysing Biomolecule Advancements through Tri-Sector Collaboration (Academia, Regulatory Bodies, and Industry). The panellists for the session will be Dr Tathagata Dutta, President & Chief Technology Officer, JODAS EXPOIM PVT LTD; Rohit Jadhav, General Manager, Analytical R&D, Kashiv Biosciences LLC; Dr Muralidharan Chandrakesan, Vice President, Aurobindo Pharma; and Dr Rajesh Bahekar, Senior General Manager, Medicinal Chemistry, New Drug Discovery, Zydus Cadila. The session will be moderated by Professor Ashutosh Kumar, Structural Biology, Department of Bioscience and Bioengineering, Indian Institute of Technology Bombay.
The workshop will conclude with the closing remarks from ETPharma.
